Intimation of restart of Pencillin-G production at our Kakinada facility post receipt of ''Consent to Operate'' from Andhra Pradesh Pollution Control Board.
Awaiting price reaction for this filing.
The company has resumed Penicillin-G manufacturing at its Kakinada plant after receiving the 'Consent to Operate' from the Andhra Pradesh Pollution Control Board. This consent was required for the plant to legally begin operations, indicating the facility was previously shut down pending regulatory clearance. The restart is a positive operational milestone, allowing the company to recommence supply of this key active pharmaceutical ingredient. No financial details, production capacity figures, or revenue impact estimates were provided in the announcement.
Positive for shareholders — restart of production should help recover lost revenue from the shutdown period and ease supply concerns. However, with no capacity or financial guidance given, the exact earnings impact remains unclear.